Drug Profile
PYM 50018
Alternative Names: Myogane; P 59; PYM50018Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Phytopharm
- Developer IXICO; Phytopharm
- Class Neuroprotectants; Small molecules; Steroid sapogenins
- Mechanism of Action Brain derived neurotrophic factor agonists; Glial cell line-derived neurotrophic factor agonists; Neuron stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Amyotrophic lateral sclerosis; Neurodegenerative disorders
Highest Development Phases
- No development reported Amyotrophic lateral sclerosis; Glaucoma
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Glaucoma in United Kingdom (PO)
- 23 May 2013 Phytopharm conducts discussions with external parties for further development of PYM 50018 under licensing arrangements
- 04 Oct 2011 Phytopharm receives a grant from the Technology Strategy Board for PYM 50018 development in Glaucoma